| Budget Amount *help |
¥43,810,000 (Direct Cost: ¥33,700,000、Indirect Cost: ¥10,110,000)
Fiscal Year 2022: ¥8,580,000 (Direct Cost: ¥6,600,000、Indirect Cost: ¥1,980,000)
Fiscal Year 2021: ¥8,580,000 (Direct Cost: ¥6,600,000、Indirect Cost: ¥1,980,000)
Fiscal Year 2020: ¥8,580,000 (Direct Cost: ¥6,600,000、Indirect Cost: ¥1,980,000)
Fiscal Year 2019: ¥8,580,000 (Direct Cost: ¥6,600,000、Indirect Cost: ¥1,980,000)
Fiscal Year 2018: ¥9,490,000 (Direct Cost: ¥7,300,000、Indirect Cost: ¥2,190,000)
|
|---|
| Outline of Final Research Achievements |
In this study, basic research was carried out with the aim of establishing a new control method for animal influenza. For avian influenza, a recombinant virus with H5/H4 chimeric HA was constructed as a nasal spray non-replicating vaccine candidate virus that can block infection itself. On the other hand, regarding companion animal influenza, in order to evaluate the potential to acquire infectivity to humans, we identified mutations required for efficient growth in human-type cells and analyzed their molecular basis. We acquired basic knowledge to prevent the outbreak of a pandemic in advance.
|
